Trial Profile
A Phase II Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma With Rearrangements of MYC and BCL2 and/or BCL6
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Devimistat (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma
- Focus Therapeutic Use
- 05 Oct 2023 Planned number of patients changed from 34 to 24.
- 05 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 31 Aug 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.